At QBRI, Dr. Narges Amini leads on innovation and commercialization of scientific research that address the strategic needs of the Institute and Qatar Foundation. In this role, Narges brings her broad and unique experiences across academia, clinical research, and the industry.
Prior to joining QBRI, Narges was the Program Director of Axovia Therapeutics, working with gene therapy pioneers to develop the first gene therapy to treat diseases caused by cilia dysfunction. At University College London (UCL), Narges was a member of the Business & Innovation Group within the Translational Research Office, tasked with enhancing the translation of biomedical research through business development and strategic partnerships with stakeholders in the healthcare sector. Within this role, she was also a founding member and Business Director of the P4 Precision Medicine Accelerator, previously the CEO of a UCL-based personalized disease risk prediction startup (StoreGene).
Narges has also worked at Imperial Innovations, guiding the translation of academic research arising from Imperial College London through the commercialization process. She has also acquired broad experience in pharmacovigilance and regulatory affairs through her work at GlaxoSmithKline and UCL Cancer Trial Centre.
Narges completed her PhD at the Imperial College NHLI Cardiovascular Sciences Unit. Narges holds an MSc in Human Molecular Genetics from Imperial College London and a BSc in Molecular Genetics from King’s College London.